Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide on QT/QTc Intervals in Participants Living With Overweight or Obesity
NCT07229157Phase 1Completed
- Sponsor
- Amgen
- Start
- Oct 2025
- Primary completion
- Aug 2026
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of maridebart cafraglutide in obesity (3 arms), sponsored by Amgen. Primary endpoint: Change from Baseline in QTcF for Maridebart Cafraglutide. Started Oct 2025; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07229157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229157.